Depression

Tucson, AZ

99 Depression Trials near Tucson, AZ

Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The study is a randomized trial comparing outcomes of active duty service members who present to the emergency department at risk for suicide and receive care from providers trained in crisis response planning versus those providing treatment as usual.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

700 Participants Needed

rTMS for Bipolar Disorder

San Diego, California
This trial is testing whether a special type of brain stimulation called high dose spaced theta-burst rTMS can help reduce depression in people with bipolar disorder who haven't responded to other treatments. The study will also look for markers in the brain that can predict who will benefit from this treatment. Theta-burst stimulation (TBS) is a newer form of repetitive transcranial magnetic stimulation (rTMS) that has shown similar or greater effects on brain activity compared to standard rTMS.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

60 Participants Needed

Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS in individuals with TRD who have previously responded to an acute course of rTMS. In the R61 phase of the study, we will recruit 75 participants across three study sites, the University of California San Diego, Weill Cornell Medicine, and Australian National University, into a double-blind, three-arm maintenance treatment trial. In this trial, participants will be randomized to receive either standard maintenance rTMS, clustered maintenance rTMS, or sham maintenance rTMS for a duration of 6 months. Our primary aim is to examine the efficacy of maintenance rTMS on sustaining connectivity between the dorsolateral prefrontal cortex (DLPFC) and subgenual cingulate cortex (SGC) measured through concurrent TMS and electroencephalography (TMS-EEG) at baseline and every six weeks throughout the 6-month treatment period. We will also assess changes in depressive symptom severity using clinical scales, including the Montgomery-Asberg Depression Rating Scale (MADRS) as a secondary outcome measure. It is hypothesized that stimulation with clustered maintenance rTMS will demonstrate superiority in sustaining DLPFC-SGC connectivity compared with standard maintenance rTMS and sham maintenance rTMS

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

75 Participants Needed

This study aims to evaluate the feasibility, safety, and tolerability of an innovative approach to treating Major Depressive Disorder (MDD), particularly in cases where patients have not responded well to traditional therapies. Specifically, the objective is to evaluate the antidepressant effects of a Dose-Optimized and Spaced Transcranial Direct Current Stimulation (DOS-tDCS) protocol in participants with treatment-resistant depression (TRD) compared to spaced tDCS only and sham tDCS in a 3-arm randomized controlled trial (RCT). The proposed method involves applying low-intensity electrical currents through the scalp in a manner that is both more intense and more frequently spaced than standard treatments. This approach is hypothesized to lead to a significant reduction in depressive symptoms. Participants in the study will be randomly assigned to one of three groups: the experimental group receiving the DOS-tDCS treatment, a group receiving spaced tDCS only, or a control group receiving a sham (placebo) treatment. Outcomes will be measured over a period of six weeks. The study's goal is to offer a potentially more accessible and effective treatment option for individuals who have not benefited from existing MDD therapies.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

75 Participants Needed

Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) - Modius Mood Study The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating major depressive disorder(MDD) , as compared to a sham control. Allocation: Randomized to either active device or control device usage. Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

170 Participants Needed

This trial tests a nasal spray drug called BPL-003 along with counseling for people whose depression doesn't get better with usual treatments. The drug aims to quickly improve mood, and counseling helps provide emotional support.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

196 Participants Needed

This trial is testing a new brain stimulation treatment to help people with hard-to-treat depression who have suicidal thoughts. The treatment uses magnetic pulses to stimulate specific brain areas several times. Researchers hope this will improve brain communication and reduce suicidal thoughts. This type of brain stimulation has been studied before and has shown positive effects.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

76 Participants Needed

The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups. Group 1 will receive a computer-based program that is designed as a cognitive training intervention and Group 2 will receive a similar computer-based exercise that researchers think will be less effective in training thinking skills (also known as a control or sham condition). Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:21 - 55

128 Participants Needed

The goal of this pilot SKY (Sudarshan Kriya Yoga) Breath Meditation study is to establish feasibility and acceptability of the intervention; and investigate preliminary effectiveness of the intervention at the DNA methylation, RNA and protein levels in blood samples collected from participants before and after the 8 week SKY intervention. Primary outcomes also include preliminary effectiveness at the physiological level using a wearable device used for continuous monitoring. Secondary outcome measures include behavioral inventories.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:21 - 99

45 Participants Needed

Active on Power

MM120 for Depression

La Jolla, California
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

140 Participants Needed

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

70 Participants Needed

This trial tests if pramipexole can help adults with anxiety or depression feel more socially connected. Pramipexole increases dopamine levels in the brain, which may improve how people respond to positive social interactions. The study will measure brain activity, behavior, and self-reported feelings before and after a period of treatment. Pramipexole has shown potential to improve mood and reduce anxiety in both experimental and clinical settings.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 50

108 Participants Needed

The goal of this open-label single-arm study is to test a meditative neurofeedback intervention for depressed mood.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

27 Participants Needed

The investigators propose a randomized 3-arm double-blinded parallel experimental trial (20 sessions over 4 weeks) in 75 patients with TRD. The three arms include (1) the combination of a fully Individualized form of intermittent Theta Burst Stimulation (iTBS) (using BOTH the frequency and electric field (E-field) targeting approaches) (Ind-iTBS)), (2) iTBS individualized using E-field targeting only (targeted-iTBS) and (3) Standard iTBS treatment (i.e., typical iTBS localized to the dorsolateral prefrontal cortex (DLPFC) using the Beam F3 method). Electroencephalography (EEG) data will be collected at rest and during a working memory task, at baseline, and at the end of treatment along with clinical assessments of depression severity. The target engagement dependent variable of interest in these three arms will be fronto-parietal theta connectivity measured through resting-state EEG. The investigators hypothesize that stimulation with Ind-iTBS will lead to greater changes in fronto-parietal theta connectivity than that produced with targeted-TBS and standard iTBS. Aim: To evaluate the effects of two individualized forms of iTBS (i.e., using BOTH the frequency and E-field individualization; Ind-iTBS) compared to iTBS individualized for E-field targeting only (targeted-iTBS) and standard iTBS on fronto-parietal theta connectivity. Hypotheses: (1) Ind-iTBS will lead to greater changes in fronto-parietal theta connectivity compared to both targeted-iTBS and standard iTBS. (2) Ind-iTBS will also lead to a greater reduction in depressive symptoms (as defined by the mean reduction in Montgomery Åsberg Depression Rating Scale Scores (MADRS)) compared to both targeted-iTBS and standard iTBS.
No Placebo Group

Trial Details

Trial Status:Recruiting

75 Participants Needed

The primary goal of this clinical trial is to evaluate whether Personalized Augmented Cognitive Training (PACT) plus intermittent theta burst stimulation (iTBS) is effective for treating depression in Service Members, Veterans, and civilians who have sustained a mild TBI. Participants will receive PACT plus 20 sessions of iTBS or sham iTBS over 4 weeks. Assessments will occur at baseline, 2 weeks, 4 weeks, and 8 weeks. Researchers will compare the PACT+iTBS group to the PACT+sham iTBS group to see if PACT+iTBS is associated with more depression improvement.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

72 Participants Needed

Veterans with comorbid chronic pain and depression are highly prevalent, have poor functional status and low quality of life, are at increased risk of suicide and lack access to effective treatments. To address this problem, the proposed research will examine the feasibility of a novel approach that integrates repetitive Transcranial Magnetic Stimulation and Acceptance and Commitment Therapy with the overall goal of maximizing functional improvement in Veterans with chronic pain and depression. This is an important first-step in preparation for a future randomized efficacy trial. The investigators will also include two cognitive control tasks with concurrent electroencephalography to explore as a potential objective indicator of treatment response. This application addresses a critical need within the Veterans Health Administration and is closely aligned with the focus area of developing suicide prevention treatments that influence participation in life roles.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

31 Participants Needed

The primary goal of this study is to evaluate whether intermittent theta burst stimulation (iTBS) is effective for treating depression in people who have depression and chronic hoarding disorder (HD). The study will also evaluate whether this treatment can improve HD symptoms, cognitive performance, and brain region connectivity. The study team will investigate how the treatment works for depression, as well as other factors that can enhance or hinder treatment, such as pre-treatment level of depression, cognitive performance, or brain region connectivity.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

12 Participants Needed

rTMS for Gulf War Syndrome

San Diego, California
This study aims to look at the effectiveness of using repetitive transcranial magnetic stimulation (rTMS) in relieving pain and other co-morbid symptoms of Gulf War Illness.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 65

204 Participants Needed

This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

240 Participants Needed

Chronic pain (CP) is a major health problem for military Veterans, and CP is often associated with comorbid mental health problems, including posttraumatic stress disorder (PTSD) and depression. CP with psychological comorbidity is associated with increased healthcare costs, medication use, risk of suicide and rates of disability and reduced quality of life. Current empirically supported treatments do not always lead to substantial improvements (up to 50% of patients drop out or are do not respond to treatment). This project was designed to evaluate the efficacy of a novel intervention for addressing these challenges. Compassion meditation (CM), a meditative practice that focuses on the wish to remove suffering, is a contemplative practice that has promise for the amelioration of physical and mental health problems as well as promoting positive affect and improving quality of life. This study will evaluate the efficacy of Cognitively-Based Compassion Training for Chronic Pain with Psychological Comorbidity (CBCT-CP+) compared to Health Education while Living with Pain (H.E.L.P.) control condition, in a sample of among Veterans with CP conditions and psychological comorbidity.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

142 Participants Needed

Why Other Patients Applied

"I was first diagnosed with major depressive disorder and anxiety over twenty years ago. I have tried different medications. Had to come off medications due to pregnancies, and have worked through different side effects like weight gain, nausea, sleepiness, and the more severe where i have tried to claw my way out of my skin it itched so bad. I dont want other people to have to go through this and I wish I could be off of my medication for good but it just hasnt happened. IF something is out there to improve the life of an anxious and/or depressed person I'd like to be able to say I helped find it."

HD
Depression PatientAge: 46

"I’m ready to move on with my life. I did a poor job bouncing back from COVID (dealing with a disability). I'd already had a PTSD diagnosis after my spouse died. These past few years have been tough and I'd like to feel like I'm alive again. I need help getting out of this phase."

FY
Depression PatientAge: 60

"I have struggled my entire life with depression. I feel like it took away half my life because I've been unable to truly feel the good times and people around me, like I'm numb. I would like to take part to see if it might help me, but I would also like to help others by doing this trial if I am accepted. I would love to enjoy life and truly feel the happy experiences that might come my way rather than observe them without feeling."

EW
Depression PatientAge: 45

"I've experienced drug resistant MDD for 2 decades. I have had no success with CBT and medication, nor either alone. I had success once with TMS, about 5 sessions, in 2014. I have not had TMS since then."

YB
Depression PatientAge: 58

"My long history of depression has been met with a long list of trial and error drugs. My current medication (generic Pristiq) has been prescribed for two decades (though I tried several other medications during my last serious episode several years ago. When the episode passed I returned to generic Pristiq. I am interested in a clinical trial because I wonder if I can do something different to more effectively avoid a serious depressive episode and lift the general malaise I often feel."

DD
Depression PatientAge: 62
Electronic screening is effective for timely detection of, and intervention for, suicidal ideation and other mental health symptoms. The VA eScreening program is a patient self-report electronic screening system that has shown promise for the efficient and effective collection of mental and physical health information among Veterans. However, additional effectiveness and implementation research is warranted to evaluate the impact of eScreening within VHA. This study will address questions of the impact of eScreening compared to screening as usual, while evaluating a multi-component implementation strategy (MCIS) for optimal enterprise rollout of eScreening in VA Transition Care Management clinics.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

69 Participants Needed

Recovery-oriented care is an imperative for the VA, particularly in mental health programming for Veterans with serious mental illness (SMI). Collaborative decision-making (CDM) is a recovery-oriented approach to treatment decision-making that assigns equal participation and obligation to patients and providers across all aspects of decision-making, thereby empowering patients and facilitating better decision-making based on patient values and preferences. CDM is associated with several important outcomes including improved treatment engagement, treatment satisfaction, and social functioning. However, current levels of CDM among Veterans with SMI are low, and there is not yet an evidence-based method to improve CDM. Improving Veteran skill sets associated with engaging in CDM is a potential intervention strategy. Collaborative Decision Skills Training (CDST) is a promising new intervention that was previously developed by the applicant for use in adult civilians with SMI and found to improve relevant skills and improve sense of personal recovery. The proposed study has two primary stages. First, a small, one-armed, open label trial will establish CDST's feasibility will evaluate CDST among 12 Veterans with SMI receiving services at the VA San Diego Psychosocial Rehabilitation and Recovery Center (PRRC) and identify and complete any needed adaptations to CDST. Stakeholder feedback from Veterans, VA clinicians, and VA administrators will be collected to assess Veteran needs and service context to identify any needed adaptations to the CDST manual or the delivery of CDST to maximize its impact and feasibility. The developers of CDST will review all feedback and make final decisions about adaptations to ensure that CDST retains its essential components to protect against loss of efficacy. For example, a recommendation to adjust role-play topics to better reflect the needs of Veterans would be accepted because it would increase CDST's relevance without impairing its integrity, but a recommendation to remove all role-plays would not be accepted because it would cause loss of a key component. Second, CDST will be compared to active control (AC) using a randomized clinical trial of 72 Veterans. The primary outcome measure will be functioning within the rehabilitation context, operationalized as frequency of Veteran CDM behaviors during Veteran-provider interactions. Secondary outcomes are treatment attendance, engagement, satisfaction, and motivation, along with treatment outcomes (i.e., rehabilitation goal attainment, sense of personal recovery, symptom severity, and social functioning). Three exploratory outcomes will be assessed: Veteran-initiated collaborative behaviors, acute service use and provider attitudes and behavior. Veterans will be randomly assigned to CDST or AC conditions. Veterans in the both groups will attend eight hour-long group sessions held over eight weeks. All Veterans will complete an assessment battery at baseline, post-intervention, and at three-month post-intervention follow-up. Following the trial and adaptation phase, the findings will be used to develop a CDST service delivery manual and design a logical subsequent study. The results of the proposed study will inform the potential for larger trials of CDST and the utility of providing CDST broadly to Veterans with SMI. The results of this study will expand current understanding of CDM among Veterans with SMI by providing data that will: 1) identify adaptations needed to optimize CDST for Veterans receiving services in PRRCs; 2) identify possible benefits of CDST; 3) inform development of alternate interventions or methods to improve CDM; and 4) further elucidate CDM and associated treatment processes among Veterans with SMI receiving VA rehabilitation services.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

39 Participants Needed

Radicle Revive for Menopause

Del Mar, California
A randomized, double-blind, placebo-controlled, direct-to-consumer trial assessing the impact of health and wellness products on hormonal health and associated health outcomes in women with menopausal health issues

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+
Sex:Female

500 Participants Needed

This trial tests a new medication in people with major depression who haven't improved with at least two other treatments. The drug works by changing brain chemicals to improve mood quickly. It has been approved for adults with difficult-to-treat depression and has been tested in various forms.

Trial Details

Trial Status:Recruiting
Age:18 - 65

90 Participants Needed

In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with treatment-refractory depression. This protocol will build on a previously published study demonstrating clinical efficacy of intermittent theta-burst stimulation (iTBS) on left dorsolateral prefrontal cortex (L-dlPFC) in a treatment refractory population.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

40 Participants Needed

This multi-center, randomized controlled feasibility trial will assess a 20-week home-based exercise intervention in youth with Multiple Sclerosis (MS). The goal is to determine the feasibility of conducting a larger, definitive trial on exercise training as a non-pharmacological approach to improve disease outcomes in this population. Participants will be randomized to either an Exercise Training group or a Mobility and Flexibility Training group. The investigators will evaluate differences between the two groups in physical activity levels, mediators of physical activity, and psychosocial outcomes. Assessments, including clinical exams, brain MRI, eye tracking, cognitive testing, blood draws, and questionnaires, will occur at baseline and after 20 weeks. Accelerometry will be done at baseline, 10 weeks, and 20 weeks to track physical activity. The primary objectives are to assess the feasibility of recruiting, retaining, and randomizing youth with MS and to evaluate adherence to the exercise intervention and coaching sessions. Exploratory objectives include examining changes in depressive symptoms, cognitive function, blood biomarkers (BDNF and irisin), brain volume, and fitness levels in response to the intervention. Approximately 40 participants will be enrolled from four sites in Canada and the United States. Primary outcomes include feasibility, acceptability, and fidelity measures. Exploratory outcomes include blood biomarkers, brain MRI, cognitive testing, and other neuropsychological measures.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:11 - 25

40 Participants Needed

Ropanicant for Depression

Oceanside, California
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

195 Participants Needed

The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:15 - 45
Sex:Female

80 Participants Needed

Diabetes mellitus is a chronic condition that affects the body's ability to process sugar effectively, which over time can increase the risk of heart disease, high blood pressure, and kidney damage. Other chronic conditions include high cholesterol, obesity, and depression. Persons with diabetes mellitus and multiple chronic conditions (DMMC) face higher risks of losing physical or mental function, experiencing other chronic conditions, and death. Most of the residents of New Mexico (NM) belong to groups at risk for developing DMMC. Finding quality healthcare is a key factor, as NM also ranks among the largest, poorest, and most rural states. Primary care providers (PCPs) most often treat DMMC patients, but healthcare teams can lack confidence in managing these complex patients and struggle to keep up with recommended guidelines. This Project ECHO model (ECHO) for DMMC, a telehealth intervention for healthcare teams, can lead to lower blood sugar levels in DMMC patients being treated at NM primary care clinics. ECHO is a "telementoring" program that trains healthcare teams to provide specialized medical care at their local clinics. This is done by connecting healthcare teams with specialist mentors at academic medical centers through videoconferencing sessions. During ECHO program sessions, groups of healthcare teams hear lectures on key topics in DMMC care from experts, and then give presentations of anonymous patient cases by a healthcare teams for discussion and to receive recommendations. This clinical pragmatic trial aims to learn if the intervention will improve patient blood sugar levels in persons with DMMC who are being treated at selected health clinic sites throughout New Mexico. The study aims to answer: * Whether a 0.5% drop in HbA1c on average can be achieved in the group whose healthcare teams are receiving the ECHO intervention compared to the comparator group, whose providers will not receive the intervention. * Whether the rate of an individual's HbA1c was greater than 8.5% at the baseline will be reduced by 15% at the end of the intervention. Researchers will compare health data for patients empaneled to healthcare teams in the study and the usual care comparator group both before and after the intervention period to see whether the ECHO model has a positive influence on test results.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

20 Participants Needed

The purpose of this study is to examine the effect that melatonin lotion has on sleep quality, the nervous system, and mental health. Melatonin is a hormone secreted by the brain that regulates sleep and might improve depression and anxiety symptoms. The goal is to determine whether melatonin in lotion form is an effective treatment for young adults with inadequate sleep and might improve mental health. Participants will fill out surveys, wear an actigraph (a wrist-worn device that measures sleep), wear a heart rate monitor (a strap worn around one's chest), and provide nightly saliva samples during treatment weeks. In one of the two treatment weeks, participants will receive a lotion that contains melatonin. During the other week they will receive a control treatment that will be lotion with no melatonin, and there will be a week in between with no treatment at all.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 21

60 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Depression clinical trials in Tucson, AZ pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Depression clinical trials in Tucson, AZ work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Tucson, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Tucson, AZ for Depression is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Tucson, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Depression medical study in Tucson, AZ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Depression clinical trials in Tucson, AZ?

Most recently, we added Collaborative Decision Skills Training for Serious Mental Illness, Qnnections for Suicidal Ideation and PRECISE for Suicide Prevention to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in Tucson, AZ?

The Depression clinics in Tucson, AZ currently recognized as Power Preferred are: IMA Clinical Research Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Clinical Research in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Phoenix in Phoenix, Arizona IMA Albuquerque in Albuquerque, New Mexico IMA Albuquerque in Albuquerque, New Mexico Red Bird Research in Las Vegas, Nevada Red Bird Research in Las Vegas, Nevada Viking Clinical Research in Temecula, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Anderson Clinical Research in Redlands, California Anderson Clinical Research in Redlands, California The Depression clinics in Tucson, AZ currently recognized as SuperSites are: Synergy San Diego in Lemon Grove, California

What are the current treatment options for depression?

Doctors use a stepped-care approach. First, most people try evidence-based talk therapy (such as CBT or interpersonal therapy), an antidepressant medicine (SSRIs are typical), or both, while also improving sleep, exercise and diet. If symptoms persist, the next “step” is to add or switch treatments—e.g., combining two medicines, adding lithium or an antipsychotic, or using brain-stimulation methods like transcranial magnetic stimulation or, for severe cases, electroconvulsive therapy; newer options such as esketamine nasal spray are reserved for treatment-resistant depression. Working with a clinician to review progress every few weeks and adjust the plan is key to finding the right mix.

When is depression considered severe?

Doctors call a depressive episode “severe” when almost all of the nine core symptoms are present at high intensity, the person’s daily life has largely shut down (can’t work, study, or manage self-care), or there are high-risk features like active suicidal thoughts, a recent attempt, or hallucinations/false beliefs. On common checklists this usually means a PHQ-9 score of 20 or higher, and it signals the need for urgent, comprehensive care—often a combination of medication, psychotherapy, and sometimes hospitalization. If you or someone you know reaches this point, treat it as an emergency and contact a mental-health professional or call/text 988 (USA) or your local crisis line right away.

Is it possible to never be depressed again?

Some people have a single episode of depression and stay well, but the risk of another episode is higher if you stop treatment too soon, have had several episodes before, or still have mild symptoms. You can greatly lower that risk by continuing the treatment that got you better for at least 6–12 months, learning relapse-prevention skills in CBT or mindfulness therapy, keeping regular sleep, exercise, and social routines, and checking in early with a professional if warning signs return. In short, there is no iron-clad guarantee you’ll never be depressed again, but staying on maintenance care and a healthy lifestyle makes long-term wellness much more likely.

What are the top 3 symptoms of depression?

Doctors look first for three core signs: 1) a low or hopeless mood that hangs around most of the day, nearly every day; 2) a marked loss of interest or pleasure in things you used to enjoy (called anhedonia); and 3) big changes in body energy—feeling drained, sleeping or eating far more or less than usual. If any of these have lasted two weeks or longer, it’s time to talk with a health professional, because other symptoms can pile on and treatment works best when started early.

Is depression a chemical imbalance?

No—depression can’t be pinned on one missing brain chemical. Research shows it arises from a mix of factors: how your brain circuits and several neurotransmitters work, your genes, long-term stress, and life circumstances all interact. Because causes differ from person to person, the most effective care is usually a combination of approaches—medication when needed, talking therapies, and lifestyle changes—worked out with your clinician.

How many people have untreatable depression?

Doctors call “untreatable” depression “treatment-resistant depression,” meaning the person has not improved after trying at least two suitable antidepressants. Large studies show this applies to roughly one-quarter to one-third of people with major depression—about 2–3 % of adults overall, or roughly 5–8 million U.S. adults in any given year. Importantly, many still respond to other options such as medication combinations, ketamine/esketamine, transcranial magnetic stimulation, or electroconvulsive therapy.

How to get out of deep depression?

Think of recovery as two tracks that run side-by-side. Track 1: get professional help right away—if you ever feel unsafe call 988 (or your local hotline), and with a clinician discuss proven treatments such as CBT, antidepressant medicine, and, when needed, newer options like ketamine, transcranial magnetic stimulation or electroconvulsive therapy. Track 2: reinforce the medical plan daily with mood-boosting basics—consistent exercise, regular sleep, balanced meals, limited alcohol or drugs, and time with supportive people—because these habits make the treatments work better and give you small, sustainable lifts while you heal.

Why is depression so hard to treat?

Depression is hard to treat because it isn’t a single disease—each person’s symptoms arise from a unique blend of brain chemistry, genetics, stress, medical issues, and life circumstances—so one-size-fits-all therapies rarely work. Without a blood test to guide choices, clinicians must try treatments sequentially, and roughly one-third of people need several steps or a combination of medication, talk therapy, lifestyle changes, or newer options like ketamine or magnetic stimulation before they feel well. The encouraging news is that persistence with a systematic plan and attention to sleep, exercise, and co-existing conditions allows most patients to eventually reach full recovery.

What are unhealthy coping mechanisms for depression?

Unhealthy coping means doing things that give quick relief but actually deepen depression—common examples include using alcohol or other drugs, overeating or not eating, oversleeping or endless screen-scrolling to avoid feelings, cutting or other self-harm, harsh self-talk and rumination, and withdrawing from friends or lashing out at them. These behaviors worsen mood, relationships, and safety; if you notice yourself relying on them, reach out to a trusted person or mental-health professional (or call your local crisis line) and ask about safer skills such as problem-solving steps, scheduled activity, or therapy.

Is it OK to have clinical depression?

Yes—having clinical depression isn’t a personal failing; it’s a common medical illness, and recognising it is the first step toward feeling better. What isn’t OK is to face it alone, because untreated depression can worsen and raise the risk of other problems, whereas most people improve with timely care such as talk therapy, medication, or a combination. If symptoms last more than two weeks or include thoughts of self-harm, book a visit with a primary-care doctor or mental-health professional and, in crisis, call 988 (U.S.) or your local emergency number—effective help and recovery are the norm when treatment is started.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security